Mohanlal Ramon, Ogenstad Stephan, Lyman Gary H, Huang Lan, Blayney Douglas W
BeyondSpring Pharmaceuticals, Inc., New York, NY, USA.
Statogen Consulting LLC, Wake Forest, NC, USA.
Cancer Invest. 2023 Apr;41(4):369-378. doi: 10.1080/07357907.2023.2179064. Epub 2023 Mar 8.
Neutropenia is the major toxicity of myelosuppressive cancer chemotherapy. Grade 4 neutropenia (Gr4N) is a measure of chemotherapy-induced neutropenia (CIN) severity. We conducted a meta-analysis of CIN data. Gr4N incidence was significantly correlated with febrile neutropenia (FN), days of severe neutropenia (DSN), and nadir absolute neutrophil count (ANC), which are all important predictors of morbidity. With a Gr4N threshold of 65%, both FN and DSN were below levels for low risk of adverse CIN outcomes. Gr4N was highly predictive for adverse CIN outcomes, and a 65% threshold demarcated low vs. high risk for FN and other adverse CIN outcomes.
中性粒细胞减少是骨髓抑制性癌症化疗的主要毒性。4级中性粒细胞减少(Gr4N)是化疗诱导的中性粒细胞减少(CIN)严重程度的一种衡量指标。我们对CIN数据进行了荟萃分析。Gr4N发生率与发热性中性粒细胞减少(FN)、严重中性粒细胞减少天数(DSN)以及最低点绝对中性粒细胞计数(ANC)显著相关,而这些都是发病率的重要预测指标。当Gr4N阈值为65%时,FN和DSN均低于不良CIN结局低风险水平。Gr4N对不良CIN结局具有高度预测性,65%的阈值划分了FN和其他不良CIN结局的低风险与高风险。